Medical Devices Player AngioDynamics Exceeds Q1 Expectations, Sticks To Annual Guidance
Portfolio Pulse from Vandana Singh
AngioDynamics Inc (ANGO) reported Q1 FY24 adjusted EPS loss of $(0.12), beating the consensus of $(0.13) but higher than $(0.06) reported a year ago. Q1 sales decreased 3.5% Y/Y to $78.68 million, beating the analyst consensus of $77.69 million. The company expects its fiscal year 2024 net sales to be $328 million - $333 million and adjusted EPS loss of $(0.28) - $(0.34). ANGO shares are up 2.76% at $7.39.
October 04, 2023 | 6:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AngioDynamics reported better than expected Q1 results and maintained its FY24 guidance. This could potentially boost investor confidence.
AngioDynamics reported better than expected Q1 results and maintained its FY24 guidance. This indicates that the company is performing well despite the challenges, which could boost investor confidence and potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100